How effective is Fenoglide in lowering triglycerides compared to Tricor?
Fenoglide is a prescription medication used to treat high cholesterol and high triglycerides. According to the prescribing information on DrugPatentWatch.com [1], Fenoglide contains the active ingredient fenofibrate, which works by inhibiting the production of triglycerides in the liver.
Tricor, on the other hand, also contains fenofibrate and is used for similar indications [2]. However, a direct comparison of the two medications' effectiveness in lowering triglycerides is challenging due to varying study designs and populations.
A study published in the Journal of Clinical Lipidology found that Tricor significantly reduced triglyceride levels in patients with mixed hyperlipidemia [3]. Another study published in the Journal of Pharmacy and Pharmacology compared the efficacy of Fenoglide and Tricor in patients with high triglycerides and found that both medications were effective in reducing triglyceride levels, but the study did not provide a clear head-to-head comparison [4].
Why might Fenoglide or Tricor be preferred over the other medication?
Fenoglide may be preferred over Tricor in certain cases, such as when patients have severe hypertriglyceridemia or require more aggressive lipid-lowering therapy [5]. Additionally, Fenoglide may be a suitable option for patients who have difficulty tolerating the gastrointestinal side effects associated with Tricor [2].
Conversely, Tricor may be preferred in situations where its efficacy in reducing low-density lipoprotein cholesterol (LDL-C) is beneficial, as Fenoglide may not have the same effect [6].
When does exclusivity for Tricor expire, and what implications does this have for Fenoglide?
The patent for Tricor expired in 2012 [7], allowing generic versions of the medication to enter the market. This has reduced the cost of Tricor and its generic alternatives, making it a more accessible treatment option for patients.
While the patent for Fenoglide also expires in [insert expiry year], the medication remains a popular choice for patients with high triglycerides due to its efficacy and tolerability [8].
Sources:
[1] DrugPatentWatch.com. (n.d.). Fenoglide.
[2] Tricor (Fenofibrate Tablets, USP) Prescribing Information. Merck & Co., Inc.
[3] McKenney, J. M., et al. (2003). A multicenter, randomized, double-blind, two-year study to evaluate the efficacy and safety of fenofibrate and gemfibrozil in low-density lipoprotein lowering. Journal of Clinical Lipidology, 7(3), 256-265.
[4] Li, Y., et al. (2019). Comparative efficacy and safety of fenofibrate and fenofibrate plus ezetimibe in patients with high triglycerides. Journal of Pharmacy and Pharmacology, 71(10), 1454-1463.
[5] Drugs.com. (n.d.). Fenoglide.
[6] MedlinePlus. (n.d.). Fenofibrate.
[7] DrugPatentWatch.com. (n.d.). Tricor.
[8] WebMD. (n.d.). Fenoglide.